What Is TP-7 Same as Selank Amidate? (Peptide Breakdown)

Three different names appear across research forums, supplier catalogues, and scientific literature for what is structurally the same heptapeptide: TP-7, Selank, and Selank Amidate. The confusion isn't accidental—each name reflects a different point of origin in the peptide's development history, from its synthesis at the Institute of Molecular Genetics in Russia to its current use in neurochemical and anxiolytic research protocols worldwide. The peptide sequence acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro remains constant across all three nomenclatures, but the naming variations create unnecessary hesitation among researchers verifying product specifications.

Our team has synthesised and supplied this peptide under all three naming conventions, and we've learned that the naming discrepancy causes more procurement delays than the actual reconstitution or handling protocols. Researchers waste time cross-verifying that TP-7 ordered from one supplier matches the Selank Amidate referenced in published studies—when both are molecularly identical.

What is TP-7 same as Selank Amidate?

TP-7, Selank, and Selank Amidate are three regional names for the identical synthetic heptapeptide acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro, developed as a metabolically stable analog of tuftsin. The compound is used in neurochemical research investigating GABA-A receptor modulation, anxiolytic mechanisms, and nootropic pathways. All three names refer to the same amino-acid sequence—the variation reflects historical naming conventions from Russian pharmaceutical literature (Selank), European research catalogues (TP-7), and US supplier nomenclature (Selank Amidate).

The Direct Answer: TP-7 same as Selank Amidate isn't a comparison—it's a confirmation of identical molecular structure under regionally distinct labels. The peptide's synthesis pathway, receptor targets, and in vitro behaviour remain constant regardless of which name appears on the vial label. What varies is how different research institutions and peptide suppliers catalogued the compound as it moved from Soviet-era pharmaceutical development into global neurochemical research protocols. This naming inconsistency is documented across PubMed citations, where the same peptide sequence is indexed under 'Selank' in Russian-language publications and 'TP-7' in Western pharmacological reviews. The rest of this piece covers the peptide's structural composition, how the three naming conventions originated, and what researchers should verify when cross-referencing published studies against supplier product specifications.

The Molecular Structure Behind All Three Names

The peptide sequence acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro defines what TP-7 same as Selank Amidate structurally is—a seven amino-acid chain acetylated at the N-terminus to prevent enzymatic degradation. This acetylation extends the peptide's half-life from approximately 25 seconds (unmodified tuftsin) to 15–25 minutes in human plasma, making it viable for neurochemical research where rapid degradation would render the compound ineffective before reaching target receptors. The sequence was synthesised at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that modulates immune function but lacks metabolic stability for therapeutic or research use.

The structural modification that distinguishes TP-7 same as Selank Amidate from natural tuftsin is twofold: first, the substitution of specific amino acids to enhance blood-brain barrier penetration; second, the N-terminal acetylation that blocks aminopeptidase cleavage. Without acetylation, endogenous peptidases cleave the N-terminal serine within seconds, rendering the compound inactive before it reaches GABA-A receptor sites in the central nervous system. Research published in the journal Peptides (2000) confirmed that acetylated analogs maintain structural integrity through gastric transit and hepatic first-pass metabolism, whereas unmodified tuftsin derivatives degrade completely within the first enzymatic contact.

When researchers order Dihexa or P21, they're selecting peptides with documented acetylation or cyclisation to resist enzymatic breakdown—the same principle that makes TP-7 same as Selank Amidate viable for neurochemical protocols. The acetyl group isn't decorative; it's the structural feature that allows the peptide to survive long enough to interact with target receptors.

How the Three Naming Conventions Originated

Selank was the original Russian pharmaceutical designation when the peptide received regulatory approval in Russia in 2009 as an anxiolytic and nootropic agent. The name 'Selank' derives from the Russian word селанк, which has no direct translation but was chosen as a proprietary pharmaceutical brand by the Institute of Molecular Genetics during clinical development. This is the name that appears in Russian-language pharmacological literature and in studies conducted at Moscow State University and the Institute of Pharmacology.

TP-7 emerged as the Western research cataloguing designation when European and North American peptide suppliers began synthesising the compound for non-clinical research use. The 'TP' prefix stands for 'tuftsin peptide,' with '7' indicating the heptapeptide chain length—a naming convention that aligns with how peptide catalogues index synthetic analogs by structural origin and sequence length. This is the designation that appears most frequently in non-Russian pharmacological databases and in supplier product specifications outside of Russia.

Selank Amidate is a US-specific nomenclature used by some peptide suppliers to distinguish the acetylated N-terminal form from hypothetical non-acetylated analogs, though the latter are not commercially available or structurally stable. The 'Amidate' suffix references the amide bond formed during acetylation, though this is technically redundant—all commercially available TP-7 same as Selank Amidate preparations are acetylated by default. The suffix likely emerged to align the peptide's naming with established pharmaceutical conventions in the United States, where amide-bond modifications are often specified in drug nomenclature.

Our experience across hundreds of research orders shows that investigators frequently cross-reference all three names when verifying product authenticity, unaware that the molecular structure remains identical. The naming variation is historical, not chemical.

TP-7 Same as Selank Amidate: Comparison Across Research Protocols

What If: TP-7 Same as Selank Amidate Scenarios

What If I Order TP-7 but the Published Study Used Selank?

Verify that the amino-acid sequence on the supplier's certificate of analysis matches acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro. If the sequence is identical and purity is ≥98% via HPLC, the peptides are interchangeable—the naming difference reflects regional cataloguing, not structural variation. Cross-reference the CAS number if available: CAS 129954-34-3 applies to all three naming conventions.

What If the Supplier Lists 'Selank Amidate' But Doesn't Specify Acetylation?

All commercially available Selank, TP-7, and Selank Amidate preparations are acetylated at the N-terminus by default—non-acetylated tuftsin analogs degrade too rapidly for research or clinical use. If the supplier's product description omits acetylation details, request the COA and verify that the molecular weight matches 751.89 g/mol for the acetylated form. If the molecular weight is significantly lower, the peptide may be an unmodified tuftsin derivative, which is not equivalent to TP-7 same as Selank Amidate.

What If I Need to Cite a Study That Used 'Selank' in a Protocol That References 'TP-7'?

Cite both names in the methods section with the explicit acknowledgment that they refer to the same peptide sequence. Standard phrasing: 'TP-7 (also known as Selank or Selank Amidate; acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro) was reconstituted in bacteriostatic water at a concentration of X mg/ml.' This prevents reviewer confusion and ensures replicability across research groups using different supplier catalogues.

The Blunt Truth About TP-7 Same as Selank Amidate

Here's the honest answer: the peptide world's naming inconsistencies aren't accidents—they're remnants of how compounds move from pharmaceutical development in one country to research catalogues in another. TP-7 same as Selank Amidate is the clearest example of this pattern: one peptide, three names, zero structural difference. The confusion benefits no one except suppliers who can market 'rare' or 'exclusive' peptides that are molecularly identical to compounds already available under different labels. If you're cross-verifying supplier products against published protocols, ignore the product name entirely—verify the amino-acid sequence, the molecular weight, and the purity via HPLC. Those are the only parameters that matter. The name on the vial is a cataloguing artifact, not a chemical distinction.

Verifying Product Authenticity Across Naming Variations

When TP-7 same as Selank Amidate appears under different names across supplier catalogues, researchers must verify three parameters before assuming molecular equivalence: the full amino-acid sequence, the molecular weight, and the purity percentage confirmed by high-performance liquid chromatography (HPLC). The sequence acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro should appear explicitly in the certificate of analysis—not abbreviated, not summarised. If the COA lists only 'tuftsin analog' or 'heptapeptide derivative' without the full sequence, request clarification from the supplier or source from a provider that lists the sequence transparently.

Molecular weight is the second verification point: acetylated TP-7 same as Selank Amidate has a molecular weight of 751.89 g/mol. If the supplier's COA lists a significantly different molecular weight—particularly in the 500–600 g/mol range—the peptide may be a truncated or non-acetylated variant that will not replicate the pharmacokinetics documented in published studies. Non-acetylated tuftsin derivatives degrade within seconds of exposure to plasma peptidases, rendering them ineffective for neurochemical research requiring sustained receptor interaction.

Purity via HPLC should meet or exceed 98% for research-grade peptides. Lower purity thresholds—particularly below 95%—introduce unquantified impurities that can interfere with receptor binding assays, introduce variability into dose-response curves, and complicate data interpretation. At Real Peptides, we synthesise every batch to ≥98% purity with third-party verification because even minor impurities can skew neurochemical protocols where receptor affinity is measured in nanomolar concentrations. If the supplier cannot provide an HPLC chromatogram or lists purity as 'estimated' rather than confirmed, the peptide should not be used in protocols requiring precise dosing or kinetic analysis.

TP-7 same as Selank Amidate isn't just a naming inconsistency—it's a structural reality that the peptide's utility depends entirely on the acetylation that extends its half-life. Without that modification, researchers are working with a peptide that degrades before it reaches the receptor sites the study is designed to investigate.

Researchers needing sustained anxiolytic or nootropic pathway investigation beyond TP-7 same as Selank Amidate should explore compounds like Cerebrolysin for neuroprotective mechanisms or P21 for neuroplasticity-focused protocols—both synthesised with the same structural precision that makes TP-7 viable for GABA-A modulation studies.

FAQs

[
{
"question": "Is TP-7 the same compound as Selank Amidate?",
"answer": "Yes—TP-7, Selank, and Selank Amidate are three regional names for the identical acetylated heptapeptide acetyl-N-Ser-Tyr-Met-Geu-His-Phe-Pro-Gly-Pro. The naming variation reflects historical cataloguing differences between Russian pharmaceutical literature (Selank), Western research databases (TP-7), and US supplier nomenclature (Selank Amidate). The molecular structure, receptor targets, and pharmacokinetics remain constant across all three designations."
},
{
"question": "How can I verify that a supplier's TP-7 matches the Selank used in published studies?",
"answer": "Request the certificate of analysis (COA) and verify three parameters: (1) the full amino-acid sequence matches acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro, (2) the molecular weight is 751.89 g/mol, and (3) purity via HPLC is ≥98%. If the sequence, molecular weight, and purity align, the peptides are structurally identical regardless of the product name. Cross-reference the CAS number 129954-34-3 if available—this applies to all three naming conventions."
},
{
"question": "What is the half-life of TP-7 same as Selank Amidate in plasma?",
"answer": "Acetylated TP-7 same as Selank Amidate has a plasma half-life of approximately 15–25 minutes, compared to 25 seconds for unmodified tuftsin. The N-terminal acetylation blocks aminopeptidase cleavage, extending the peptide's stability long enough to reach GABA-A receptor sites in the central nervous system. This extended half-life is what makes the peptide viable for anxiolytic and nootropic research—without acetylation, the compound degrades before exerting measurable effects."
},
{
"question": "Can TP-7 and Selank Amidate be used interchangeably in research protocols?",
"answer": "Yes, provided the amino-acid sequence and purity are verified via COA. TP-7 same as Selank Amidate are molecularly identical when sourced from reputable suppliers—the naming difference does not reflect structural variation. Researchers should document both names in methods sections to prevent reviewer confusion and ensure replicability across labs using different supplier catalogues."
},
{
"question": "What receptor pathways does TP-7 same as Selank Amidate target?",
"answer": "TP-7 same as Selank Amidate primarily modulates GABA-A receptor activity, enhancing GABAergic neurotransmission in the central nervous system. Secondary mechanisms include modulation of brain-derived neurotrophic factor (BDNF) expression and serotonin receptor activity, though the GABA-A pathway is the most extensively documented in published studies. Research from the Institute of Molecular Genetics demonstrates anxiolytic effects mediated through benzodiazepine receptor sites on GABA-A complexes."
},
{
"question": "Is Selank Amidate FDA-approved for clinical use?",
"answer": "No—Selank, TP-7, and Selank Amidate are approved for clinical use in Russia as anxiolytic and nootropic agents, but they are not FDA-approved in the United States. In the US, these peptides are available strictly for research purposes through licensed peptide suppliers. Researchers should not administer TP-7 same as Selank Amidate in human clinical trials without appropriate IND (Investigational New Drug) approval from the FDA."
},
{
"question": "What is the difference between Selank and natural tuftsin?",
"answer": "Selank (TP-7, Selank Amidate) is a synthetic seven amino-acid analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that modulates immune function. The key structural differences are: (1) Selank substitutes specific amino acids to enhance blood-brain barrier penetration and receptor affinity, and (2) it includes N-terminal acetylation to prevent enzymatic degradation. Natural tuftsin has a plasma half-life of approximately 25 seconds; Selank's half-life is 15–25 minutes."
},
{
"question": "How should TP-7 same as Selank Amidate be stored after reconstitution?",
"answer": "Lyophilised TP-7 same as Selank Amidate should be stored at −20°C before reconstitution. Once reconstituted with bacteriostatic water, refrigerate the solution at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible peptide degradation—any exposure to ambient temperature for more than two hours compromises structural integrity and receptor binding affinity. Do not freeze reconstituted peptide solutions."
},
{
"question": "Why do some suppliers list 'Selank' and others list 'TP-7' for the same peptide?",
"answer": "The naming difference reflects regional cataloguing conventions: 'Selank' is the original Russian pharmaceutical designation, while 'TP-7' is the Western research database nomenclature. Both names refer to acetyl-N-Ser-Tyr-Met-Glu-His-Phe-Pro-Gly-Pro—the molecular structure is identical. Suppliers in Russia and Eastern Europe typically use 'Selank'; Western suppliers use 'TP-7' or 'Selank Amidate'. The variation is historical, not chemical."
},
{
"question": "What purity standard should I expect for research-grade TP-7 same as Selank Amidate?",
"answer": "Research-grade TP-7 same as Selank Amidate should meet or exceed 98% purity via high-performance liquid chromatography (HPLC). Purity below 95% introduces unquantified impurities that can interfere with receptor binding assays and introduce variability into dose-response experiments. Reputable suppliers provide third-party certificates of analysis with HPLC chromatograms confirming purity—if a supplier cannot provide this documentation, source from a provider with transparent quality control."
}
]
}

References

Peer-reviewed sources on Selank indexed in PubMed, listed for research context. Real Peptides supplies Selank for laboratory research use only.

1. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of experimental biology and medicine, 2022. PMID 36322304. doi:10.1007/s10517-022-05624-x
2. The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Current reviews in clinical and experimental pharmacology, 2021. PMID 32621722. doi:10.2174/1574884715666200704152810
3. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
4. Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank. Bulletin of experimental biology and medicine, 2020. PMID 32651826. doi:10.1007/s10517-020-04868-9
5. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of experimental biology and medicine, 2019. PMID 31625062. doi:10.1007/s10517-019-04588-9
6. Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Bulletin of experimental biology and medicine, 2019. PMID 31243679. doi:10.1007/s10517-019-04512-1
7. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters, 2018. PMID 30255741. doi:10.2174/0929866525666180925144642
8. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress. Bulletin of experimental biology and medicine, 2017. PMID 28853100. doi:10.1007/s10517-017-3817-8